Navigation Links
Pharmos Corporation Reports 2008 Second Quarter Results
Date:8/7/2008

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second quarter 2007. Cash and cash equivalents totaled $9.0 million at June 30, 2008.

The decrease in net loss for the second quarter 2008 is due primarily to a 46% decrease in operating expenses to $2.6 million from $4.9 million in the second quarter 2007. The decline in operating expenses resulted from a 41% decrease in gross research and development expenses to $2.1 million compared to $3.7 million in the second quarter 2007. Also general and administrative expenses decreased 66% to $0.5 million from $1.3 million in the second quarter 2007.

During the second quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial is expected to enroll approximately 480 patients in about 70 sites in the United States. Costs of $1,470,000 were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. During the second quarter, the Company engaged a second CRO to identify and manage additional sites. As the Company is currently behind its planned enrollment schedule, additional expenses were incurred in conducting a centralized advertising campaign to enhance patient enrollment. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc which closed in October 2006. The continued development of this compound through late-stage clinical testing will
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Pharmos Corporation Reports 2008 First Quarter Results
3. Pharmos Corporation Completes Initial Closing of Private Placement
4. Pharmos Corporation Announces Board and Management Changes
5. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
6. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
7. Pharmos Corporation Reports 2007 Third Quarter Results
8. Pharmos Issues Letter to Shareholders
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
11. PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation ... combination products , in particular, drug/device combinations. The current system received a score of ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Finding gooey or ... is quite normal. Although there are a considerable number of terms in popular use ... this post-sleep material is a mixture of mucus, blood cells, skin cells and dust, ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2
... Stevens Institute of Technology and NACE International, ... Section, will host the Winter 2007 Corrosion Symposium: ... Charles V. Schaefer, Jr. School of Engineering & ... Keith Sheppard, a professor materials engineering, will welcome ...
... offers innovative casting, splinting and bracing technology, ... Enova Medical Technologies,Inc. of St. Paul, Minn., ... are pleased to announce the launch of ... develop and commercialize innovative orthopedic,support devices. ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... received notification from the NASDAQ Listing,Qualifications Department that ... million,market value of listed securities requirement for continued ... NASDAQ Marketplace Rule 4310(c)(3)(B).,In accordance with Marketplace Rule ...
Cached Biology Technology:Enova Medical Launches Exos Corporation 2Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq 2
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... WASHINGTON, Jan. 20The Optical Society (OSA) today announced ... biomedical optics and photonics. Biomedical Optics Express ... monthly issues, joining OSA,s portfolio of 12 peer-reviewed optics ... at Duke University, will serve as the editor-in-chief. ...
... human research that blueberries one of the richest ... improve memory. They said the study establishes a basis ... really deserve their growing reputation as a memory enhancer. ... Journal of Agricultural and Food Chemistry , a bi-weekly ...
... applications ranging from medical devices such as MRIs to surveillance ... of 1996, Congress directed the government to sell essentially all ... government for its investment in the helium and its storage. ... from the National Research Council, assesses whether selling off the ...
Cached Biology News:OSA to launch new journal: Biomedical Optics Express 2
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ANTI GELSOLIN...
Biology Products: